Spots Global Cancer Trial Database for afuresertib
Every month we try and update this database with for afuresertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) | NCT02235740 | Cancer | Afuresertib Carfilzomib | 18 Years - | Novartis | |
| Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib | NCT02040480 | Cancer | GSK2110183 Gela... GSK2110183 IR T... | 18 Years - 40 Years | GlaxoSmithKline | |
| Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients | NCT02177682 | Neoplasms, Haem... | Afuresertib | 20 Years - | Novartis | |
| Study of Afuresertib Combined With Paclitaxel in Gastric Cancer | NCT02240212 | Cancer | Afuresertib Paclitaxel | 18 Years - | Novartis | |
| Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian | NCT04374630 | Platinum-resist... | Paclitaxel Afuresertib | 18 Years - | Laekna Limited | |
| Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer | NCT04851613 | Breast Cancer | Afuresertib | 18 Years - | Laekna Limited | |
| Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone | NCT02380313 | Cancer | Afuresertib Enzalutamide Abiraterone Prednisone | 18 Years - | GlaxoSmithKline | |
| Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib | NCT02040480 | Cancer | GSK2110183 Gela... GSK2110183 IR T... | 18 Years - 40 Years | GlaxoSmithKline | |
| A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) | NCT02235740 | Cancer | Afuresertib Carfilzomib | 18 Years - | Novartis | |
| Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer | NCT04851613 | Breast Cancer | Afuresertib | 18 Years - | Laekna Limited | |
| Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | NCT05383482 | Solid Tumor NSCLC Cervical Cancer Endometrial Can... Esophageal Canc... Gastric and Gas... | Afuresertib Nab paclitaxel Docetaxel Sintilimab | 18 Years - | Laekna Limited | |
| Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib | NCT02040480 | Cancer | GSK2110183 Gela... GSK2110183 IR T... | 18 Years - 40 Years | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
